The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Abstract
BACKGROUND: Complex visual hallucinations (VHs) occur in several pathologic conditions; however, the neural mechanisms underlying these symptoms remain unclear. Although dopamine may have a role, indirect evidence indicates that serotonin may also contribute to the pathogenesis of complex VHs, probably via involvement of the serotonin 2 receptor. OBJECTIVE: To examine for the first time in vivo changes in serotonin 2A receptor neurotransmission among patients having Parkinson disease (PD) with VHs. DESIGN: Case-control study. SETTING: Academic research. PATIENTS: Seven patients having PD with VHs and 7 age-matched patients having PD without VHs were recruited. MAIN OUTCOME MEASURES: We used the selective serotonin 2A receptor ligand setoperone F 18 during positron emission tomography among nondemented patients having PD with VHs. RESULTS: Patients having PD with VHs demonstrate increased serotonin 2A receptor binding in the ventral visual pathway (including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex) as well as the bilateral dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula. CONCLUSIONS: This pilot study provides the first in vivo evidence suggesting a role for serotonin 2A receptors in mediating VHs via the ventral visual pathway in PD. Treatment studies should be performed using selective serotonin 2A receptor antagonists, which have important implications for the clinical management of VHs and psychosis in PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This finding may suggest that this receptor may be facilitating cortical disinhibition, consistent with previous proposals42,43 and studies showing 5-HT2A antagonists reducing psychosis-like symptoms20,42.”
From Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis (2026) · cites this paper as [43]
In the citing paper
“exploratory analyses using PET receptor atlases revealed a positive correlation between cortical 5-HT2A receptor distribution and abnormal MMN source activity in PD-VH, consistent with the known role of serotonin in cortical disinhibition53 and psychosis42,43”
From Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis (2026) · cites this paper as [43]
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,714
A systematic review of prevalence studies of depression in Parkinson's disease
Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008) · Movement Disorders · doi:10.1002/mds.21803 · Cited by 1,239
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model
Gunn, R. N., Lammertsma, A. A., Hume, S. P., & Cunningham, V. J. (1997) · NeuroImage · doi:10.1006/nimg.1997.0303 · Cited by 1,085
Haxby, J., Horwitz, B., Ungerleider, L. G., Maisog, J. M., Pietrini, P., & Grady, C. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-11-06336.1994 · Cited by 1,065
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fénelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,035
Depression rating scales in Parkinson's disease: Critique and recommendations
Schrag, A. E., Barone, P., Brown, R. G., Leentjens, A. F. G., McDonald, W. M., STARKSTEIN, S. E., Weintraub, D. A., Poewe, W. H., Rascol, O., Sampaio, C., et al. (2007) · Movement Disorders · doi:10.1002/mds.21333 · Cited by 690
Cited by
Sorted by citations
Items 201–266 of 266
Li, W., Lao–Kaim, N. P., Li, R., Martín‐Bastida, A., Roussakis, A., Searle, G. E., Valle‐Guzman, N., Dayal, V., Athauda, D. S., Kefalopoulou, Z. M., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf308 · Cited by 1
Chen, Y.-S., Yang, S., Lu, K.-Y., et al. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.v16.i4.114462 · Cited by 1
Stampacchia, S., Bernasconi, F., Ville, D. V. D., Amico, E., Kohoutová, L., Taylor, J., Thomas, A. J., Pagonabarraga, J., Kulisevsky, J., & Blanke, O. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00657-x · Cited by 1
Vision: Elementary and Complex Visual Processing
Hoffmann, M. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-33181-2_4 · Cited by 1
Modern approaches to treatment of psychosis in Parkinson’s disease
Cozac, V. (2016) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2016116101103-109 · Cited by 1
G protein-coupled receptors in neurodegenerative diseases
Guimarães, T. R., & Thathiah, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00017-9 · Cited by 1
Knowledge domain and emerging trends in visual hallucination research: A scientometric analysis
Zhong, M., Wu, Z., Jiang, X., Shen, B., Zhu, J., & Zhang, L. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i8.491 · Cited by 1
Pharmacotherapy of Psychosis in Parkinson’s Disease
Kwan, C., Frouni, I., & Huot, P. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_439-1 · Cited by 1
Pharmacotherapy of Psychosis in Parkinson’s Disease
Kwan, C., Frouni, I., & Huot, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_439 · Cited by 1
The treatment of visual hallucinations at present and in the future
Perry, E. K., Mosimann, U. P., & Collerton, D. (2014) · Wiley eBooks · doi:10.1002/9781118892794.ch14 · Cited by 1
Aarsland, D., Cummings, J. L., Weintraub, D., & Chaudhuri, К. R. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139856669.002 · Cited by 1
Hallucinations et maladie de Parkinson
Poisson, A., & Thobois, S. (2013) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(13)27524-x · Cited by 1
Reader response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis
Lawler, A., Torres-Yaghi, Y. A., Amjad, F., et al. (2018) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000467 · Cited by 1
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: An Open-Label Pilot TrialPreprint
Bradley, E., Sakai, K., Fernandes‐Osterhold, G., Szigeti, B., Ludwig, C., Ostrem, J. L., Tanner, C. M., Bock, M., Llerena, K., Finley, P. R., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4871260 · Cited by 1
Piccini, P. P., Li, W., Lao–Kaim, N. P., Li, R., Martín‐Bastida, A., Roussakis, A., Searle, G. E., Guzman, N. V., Dayal, V., Athauda, D. S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4567266/v1 · Cited by 1
Vignando, M., Ffytche, D., Mazibuko, N., Palma, G., Bhat, A., Montagnese, M., Dave, S., Tai, Y. F., Batzu, L., Leta, V., et al. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00669-7
“…sensitivity to perturbations, exploratory analyses using PET receptor atlases revealed a positive correlation between cortical 5-HT 2A receptor distribution and abnormal MMN source activity in PD-VH, consistent with the known role of serotonin in cortical disinhibition 53 and psychosis 42,43 .”
Yokukansan Ameliorates Psychiatric Problems in Parkinson’s Disease
Hatano, T., & Hattori, N. (2014) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.60.529
Specific neuropsychiatric disorders
Aarsland, D., Cummings, J. L., Weintraub, D., & Chaudhuri, К. R. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139856669.011
Allucinazioni e malattia di Parkinson
Poisson, A., & Thobois, S. (2014) · EMC - Neurologia · doi:10.1016/s1634-7072(14)67224-x
Managing Psychosis in Parkinson’s Disease
Friedman, J. H. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.22
Visual Hallucinations in Parkinson Disease and the Serotonin
Silver, J. (2010) · Journal watch · doi:10.1056/jp201005100000003
Aarsland, D., Cummings, J. L., Weintraub, D. A., & Chaudhuri, К. R. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139856669.006
Bernal-Pacheco, Ó., & Fernandez, H. H. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139856669.015
Imaging of Dopamine and Serotonin Receptors and Transporters
Felicio, A. C., & Stoessl, A. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418677-4.00010-5
Imaging and behavior in Parkinson’s disease: functional imaging
Nordberg, A. K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139856669.009
Functional Imaging to Study Movement Disorders
Sako, W., Uluğ, A. M., & Eidelberg, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00012-3
Parkinson’s disease: pathology, anatomy, and behavior
Burdick, D. J., & Leverenz, J. B. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139856669.003
Hallucinations in Neurological Disorders
Fonzo, A. D., Monfrini, E., Basilico, P., & Arighi, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-75124-5_7
Regularly monitor neuropsychiatric symptoms in Parkinson’s disease and adjust treatment as necessary
Writers, A. M. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-018-00598-1
Mghari, D. C. (2019) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2019.09.008
Treatment of Parkinson’s Disease Psychosis
Borek, L. L., & Friedman, J. H. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-00192-w
Neuropsychiatric Symptoms in the Course of Parkinson’s Disease
Rothenberg, K. G. (2020) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2020.28.004713
Montagnese, M., Vignando, M., Ffytche, D. H., & Mehta, M. A. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3745799
Serotonergic neural network related to behavioral inhibition systemPreprint
Kojima, K., Hirano, S., Kimura, Y., Seki, C., Ikoma, Y., Takahata, K., Ito, T., Yokokawa, K., Hashimoto, H., Kawamura, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.09.451787
VISUAL DISTURBANCES IN PARKINSON’S DISEASE PATIENTS
Tohănean, N., Muntean, L. N., Demea, H., & Perju‐Dumbravă, L. (2015) · Romanian Journal of Neurology · doi:10.37897/rjn.2015.4.2
P.0858 Psilocin induces perceptual alterations in rats: visual discrimination study
Vejmola, Č., Syrová, K., Koudelka, V., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.715
PET and SPECT in Psychiatric Complications of Parkinson’s Disease
Kaasinen, V. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_8
Rojas‐Fernandez, C. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-27883-4_2
Drug-Induced Non-Motor Symptoms in Parkinson’s Disease
Aquino, C. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009039291.020
Neuropsychiatric (Behavioral) Symptoms in Parkinson’s Disease
Rothenberg, K. G. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009039291.009
Ffytche, D. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.23538-4
Management of treatment-related behavioral disturbances in Parkinson's disease
Pandya, M. A., Nacopoulos, D. A., & Khokhar, N. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107284210.014
Traitements non médicamenteux et neurochirurgicaux de la maladie de Parkinson
Houéto, J., & Erraud, J. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-76331-1.00024-0
Functional MRI in familial and idiopathic PD
Verghese, J. P., de Natale, E. R., & Politis, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821651-4.00007-5
Serotonergic molecular imaging in familial and idiopathic PD
Pagano, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821651-4.00018-x
Meyer, J. M., & Stahl, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108553575.003
Khan, A. F., Adewale, Q., Lin, S., Baumeister, T. R., Zeighami, Y., Carbonell, F., Palomero‐Gallagher, N., & Iturria‐Medina, Y. (2023) · medRxiv · doi:10.1101/2023.03.22.23287578
Acute psychiatric problems in movement disorders
Urso, D., Vacchiano, V., Rizzo, G., & Logroscino, G. (2023) · International review of movement disorders · doi:10.1016/bs.irmvd.2023.08.002
Neuropsychiatric Manifestations in Parkinson Disease
Weintraub, D. A., Gallagher, J., & Stern, M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108989855.015
PET and SPECT in Psychiatric Complications of Parkinson’s Disease
Kaasinen, V. (2014) · Springer eBooks · doi:10.1007/978-3-642-40384-2_10
Miller, C. O. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-13315-1_5
A structural overview of G-protein-coupled receptors in neurological disorders
Gupta, O. D., Chakraborty, I., & Pal, K. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01712-6
Neumane, S. (2011) · theses.fr (ABES) · doi:10.70675/4cb9b747z6b13z46eazb3cbzb58a8bffabf2
Network dynamic of basal ganglia circuits in normal and parkinsonian conditions
Guilhemsang, L. (2022) · theses.fr (ABES) · doi:10.70675/5aef585bz9e13z4c2azb362z88cbd3805666
Yates, J. R. (2026) · Springer eBooks · doi:10.1007/978-3-032-15602-0_3
Avanesyan, H., Parsadanyan, M. A., Shahinyan, M. A., Багдасарович, Л. А., Mikaelyan, M. S., Grigoryan, S. V., & Vardevanyan, P. O. (2025) · Neurophysiology · doi:10.1007/s11062-026-10001-9
Venkatesh, S., Prisinzano, H., Lipari, N., Nardiello, J., Budrow, C., McManus, G., Wheelis, E., Manfredsson, F. P., Tseng, K. Y., Stokes, A. M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9917408/v1
Cellular mechanisms of serotonergic psychedelics - apical hypercontextualisation
Kaup, K., Jiménez, J. H., & Aru, J. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106876
Inflammation and neuropsychiatric symptoms in Parkinson's disease: a genetic association
Gonçalves, A. R., Mendes, A., Damásio, J., Vila‐Chã, N., Boleixa, D., Santos, C., Leal, B., & Cavaco, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1877657
Update on Parkinson’s Disease Psychosis: Epidemiology, Mechanisms and Management
Kruse, C., Weintraub, D. A., Duda, J. E., & Morley, J. F. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01014-x
Monopoli, G., Tomaiuolo, F., Sestieri, C., Punzi, M., Marino, S., Gambi, F., Perrucci, M. G., Ferretti, A., Sensi, S. L., & Pizzi, S. D. (2026) · Brain Communications · doi:10.1093/braincomms/fcag357
Circuit mechanisms of psychotic symptoms across disorders
Braun, U., Wolf, J., Hirjak, D., Schwarz, E., Tost, H., & Meyer‐Lindenberg, A. (2026) · Neuron · doi:10.1016/j.neuron.2026.09.011
Metadata
- Authors
- Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H.
- Affiliations
- Montreal Neurological Institute and Hospital (CA)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2010-04-01
- Volume
- 67
- Issue
- 4
- Pages
- 416-21
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2026136738
- Cited by
- 266
- References
- 29
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 8 · 2023: 12 · 2022: 14 · 2021: 17 · 2020: 21 · 2019: 18 · 2018: 19 · 2017: 24 · 2016: 26 · 2015: 8 · 2014: 19 · 2013: 25 · 2012: 7
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- 5-HT2A receptor, complex visual hallucinations, Parkinson's disease, ventral stream, serotonergic neurotransmission, dopamine, receptor binding imaging, prefrontal cortex, fusiform gyrus, inferotemporal cortex
- MeSH terms
- Aged, Brain, Brain Mapping, Female, Hallucinations, Humans, Male, Middle Aged, Parkinson Disease, Pilot Projects, Pyrimidinones, Serotonin, Serotonin Antagonists, Temporal Lobe, Visual Cortex, Visual Pathways, Case-Control Studies, Receptor, Serotonin, 5-HT2A, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
